Evogene Granted 180-Day Extension to Avoid Nasdaq Delisting…

Event summary

Evogene received a 180-day extension from Nasdaq to regain compliance with the $1 minimum bid price requirement, extending the deadline to March 29, 2027.
The company's shares have been trading below $1 since March 30, 2026, initially triggering a September 28, 2026 compliance deadline.
Evogene may consider a reverse share split or other measures if it fails to meet the bid price requirement.
The company's listing on the Tel Aviv Stock Exchange remains unaffected.

The big picture

Evogene's struggle to maintain its Nasdaq listing highlights the challenges faced by small-cap biotech and agchem companies in volatile markets. The extension buys time but underscores the need for strategic moves to restore investor confidence. The situation reflects broader trends in regulatory scrutiny and market pressures on firms with innovative but unproven technologies.

What we're watching

Share Price Recovery: Whether Evogene can stabilize its share price above $1 within the extended compliance period.
Reverse Split Feasibility: The potential impact of a reverse share split on investor sentiment and liquidity.
Operational Priorities: How the company balances compliance efforts with its core focus on drug and ag-chemical development.